PYXS (STOCKS)
Pyxis Oncology, Inc. Common Stock
$1.300300
-0.049700 (-3.68%)
Prev close: $1.350000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas Civik
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $84.37M
- Employees
- 44
- P/E (TTM)
- -0.85
- P/B (TTM)
- 1.22
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.35 | $-0.35 | -0.0047 | -1.36% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.36 | +0.0587 | +16.36% |
|
Mar 2025 (Q1)
|
$-0.35 | $-0.30 | -0.0501 | -16.71% |
|
Dec 2024 (Q4)
|
$-0.25 | $-0.34 | +0.0866 | +25.73% |
Financial Statements
| Revenues | $2.82M |
| Benefits Costs and Expenses | $101.79M |
| Costs And Expenses | $101.79M |
| Nonoperating Income/Loss | $7.23M |
| Operating Expenses | $109.01M |
| Research and Development | $66.01M |
| Other Operating Expenses | $43.01M |
| Operating Income/Loss | -$106.19M |
| Income/Loss From Continuing Operations After Tax | -$97.09M |
| Income/Loss From Continuing Operations Before Tax | -$98.97M |
| Income Tax Expense/Benefit | -$1.88M |
| Net Income/Loss | -$97.09M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$97.09M |
| Net Income/Loss Available To Common Stockholders, Basic | -$97.09M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.58 |
| Diluted Earnings Per Share | -$1.58 |
| Basic Average Shares | 62,781,013 |
| Diluted Average Shares | 62,781,013 |
| Assets | $105.60M |
| Current Assets | $83.07M |
| Cash | $76.30M |
| Prepaid Expenses | $5.35M |
| Other Current Assets | $1.43M |
| Noncurrent Assets | $22.53M |
| Fixed Assets | $8.46M |
| Intangible Assets | $2.43M |
| Other Non-current Assets | $11.64M |
| Liabilities | $36.83M |
| Current Liabilities | $19.38M |
| Accounts Payable | $9.76M |
| Other Current Liabilities | $9.63M |
| Noncurrent Liabilities | $17.44M |
| Equity | $68.78M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $68.78M |
| Liabilities And Equity | $105.60M |
| Net Cash Flow From Operating Activities | -$72.37M |
| Net Cash Flow From Operating Activities, Continuing | -$72.37M |
| Net Cash Flow From Investing Activities | $69.25M |
| Net Cash Flow From Investing Activities, Continuing | $69.25M |
| Net Cash Flow From Financing Activities | -$25.00K |
| Net Cash Flow From Financing Activities, Continuing | -$25.00K |
| Net Cash Flow | -$3.14M |
| Net Cash Flow, Continuing | -$3.14M |
| Comprehensive Income/Loss | -$97.37M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$97.37M |
| Other Comprehensive Income/Loss | -$282.00K |